TACE术联合自体CIK细胞治疗原发性肝癌的临床研究

Transarterial chemoembolization combined with autologous cytokine-induced killer cells therapy for primary liver cancer

目的:探讨肝动脉栓塞化疗(TACE)术联合自体细胞因子诱导的杀伤(CIK)细胞过继性免疫治疗原发性肝癌的临床效果。方法:将38例原发性肝癌患者分成观察组(TACE联合CIK治疗20例)和对照组(单纯TACE治疗18例),比较两组术后的生活质量(QOL)、免疫功能变化、无进展生存期(PFS)和总生存期(OS)。结果:观察组术后生活质量评分改善率明显高于对照组(P<0.05);与术前比较,观察组CD3+,CD4+细胞百分率,CD4+/CD8+比值明显上升,CD8+细胞百分率明显下降(均P<0.05),而对照组以上指标无明显变化(均P>0.05);观察组平均PFS和OS为12个月和34个月,而对照组为7个月和13个月,两组间差异有统计学意义(均P<0.05)。结论:辅助性CIK细胞过继性免疫治疗可以提高TACE的疗效,明显提高原发性肝癌患者的生活质量。

Objective： To investigate the clinical efficacy of transarterial chemoembolization（TACE） therapy combined with autologous cytokine-induced killer（CIK） cells adoptive immunotherapy for primary hepatic carcinoma（HCC）. Methods： Thirty-eight HCC patients were designated to observational group（20 cases undergoing TACE plus CIK cells treatment） and control group（18 cases undergoing TACE only）.The quality of life（QOF）,immunity function alterations,progression-free survival（PFS） and overall survival（OS） between the two groups after operation were compared. Results： The improvement rate of QOL in observational group was significantly higher than that in control group after operation（P〈0.05）.Compared with the status before operation,the percentage of CD3＋ and CD4＋ cells and CD4＋/CD8＋ ratio were significantly increased while the percentage of CD8＋ cells was significantly decreased after operation in observational group（all P〈0.05）,but these indices showed no obvious difference in control group（all P〈0.05）.The average PFS and OS in observational group was 12 and 34 months,and in control group was 7 and 13 months respectively,and the differences between the two groups had statistical significance（both P〈0.05）. Conclusion： The adjuvant CIK cells adoptive immunotherapy can increase the efficacy of TACE for HCC,and improve the patients＇ QOL.